✨
AI Summary
- Analysis of declining biopharma M&A metrics in Q2/Q3.
- Discussion with CFOs from Frontier Medicines and Generate Biomedicines.
- Impact of US election results on future M&A.
Guests on This Episode
MM
Michael McCaughan
3 podcast appearances